These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 36729996)

  • 21. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences.
    Williams MT; Davis AK; Xin Y; Sepeda ND; Grigas PC; Sinnott S; Haeny AM
    Drugs (Abingdon Engl); 2021; 28(3):215-226. PubMed ID: 34349358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.
    Raison CL; Jain R; Penn AD; Cole SP; Jain S
    Front Psychiatry; 2022; 13():831092. PubMed ID: 35370864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users.
    Fauvel B; Kangaslampi S; Strika-Bruneau L; Roméo B; Piolino P
    J Psychoactive Drugs; 2023; 55(2):170-179. PubMed ID: 35384730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.
    Barrett FS; Robbins H; Smooke D; Brown JL; Griffiths RR
    Front Psychol; 2017; 8():1238. PubMed ID: 28790944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline Power of Theta Oscillations Predicts Mystical-Type Experiences Induced by DMT in a Natural Setting.
    Tagliazucchi E; Zamberlan F; Cavanna F; de la Fuente L; Romero C; Sanz Perl Y; Pallavicini C
    Front Psychiatry; 2021; 12():720066. PubMed ID: 34803754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects.
    Olson DE
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):563-567. PubMed ID: 33861218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity.
    Hartogsohn I
    Front Neurosci; 2018; 12():129. PubMed ID: 29559884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care.
    Yaden DB; Earp BD; Griffiths RR
    Camb Q Healthc Ethics; 2022 Oct; 31(4):464-471. PubMed ID: 36398520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
    Roseman L; Nutt DJ; Carhart-Harris RL
    Front Pharmacol; 2017; 8():974. PubMed ID: 29387009
    [No Abstract]   [Full Text] [Related]  

  • 35. Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.
    Peill JM; Trinci KE; Kettner H; Mertens LJ; Roseman L; Timmermann C; Rosas FE; Lyons T; Carhart-Harris RL
    J Psychopharmacol; 2022 Jan; 36(1):31-45. PubMed ID: 34983255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meditation trips: A thematic analysis of the combined naturalistic use of psychedelics with meditation practices.
    Azmoodeh K; Thomas E; Kamboj SK
    Exp Clin Psychopharmacol; 2023 Jun; 31(3):756-767. PubMed ID: 36534415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding subjective experience in psychedelic-assisted psychotherapy: The need for phenomenology.
    Miceli McMillan R; Fernandez AV
    Aust N Z J Psychiatry; 2023 Jun; 57(6):783-788. PubMed ID: 36384307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study.
    Kaup KK; Vasser M; Tulver K; Munk M; Pikamäe J; Aru J
    Front Psychiatry; 2023; 14():1088896. PubMed ID: 36937731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-lasting subjective effects of LSD in normal subjects.
    Schmid Y; Liechti ME
    Psychopharmacology (Berl); 2018 Feb; 235(2):535-545. PubMed ID: 28918441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.